Date issuedProductSafety information
17/03/41 FEGONA®

FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception ​. CLICK HERE​​​​​

22/02/41 Zofran®

Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron)  . CLICK HERE​​​​​​

20/01/41 Methotrexate "Ebewe”

​Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE "EBEWE “ for autoimmune diseases ​CLICK HERE​​​​​

12/01/41 Roaccutne

Roaccutne (isotretinoin): An update on neuropsychiatric disorders.CLICK HERE​​​​

25/12/40 soliqua (lixisenatide /insuline glargin) soliqua

(lixisenatide /insuline glargin):  Important information on dosing.CLICK HERE​​​

25/12/40 Advaquin ( levofloxacin)

Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection.CLICK HERE​​​

07/12/40 Gilenya (fingolimod)

Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception.CLICK HERE​​​​

28/10/40 Darzalex (Daratumumab)

Darzalex (Daratumumab): New identified risk of hepatitis B reactivation.CLICK HERE​​​

24/10/40 Lemtrada® Alemtuzumab

Alemtuzumab (Lemtrada): New safety information.CLICK HERE​​

09/10/40 Apixaban, Edoxaban, Dabigatran and Rivaroxaban

Direct Healthcare Professional Communication (DHPC) for the Direct Oral Anticoagulants (DOACs) Apixaban, Edoxaban, Dabigatran and Rivaroxaban.CLICK HERE​​

12345...الأخيرة